Wellbutrin (Bupropion) Should Be Tapered When Discontinuing
Yes, Wellbutrin should be tapered when discontinuing, particularly for patients on 300 mg daily doses—reduce to 150 mg once daily before complete discontinuation. This is explicitly stated in the FDA-approved prescribing information 1.
FDA-Mandated Tapering Protocol
The official FDA drug label provides clear guidance:
- For patients on 300 mg daily: Decrease to 150 mg once daily prior to discontinuation 1
- For patients on 150 mg daily: The label does not specify mandatory tapering, though clinical judgment should guide this decision
- For Seasonal Affective Disorder: Taper and discontinue in early spring; patients on 300 mg should decrease to 150 mg before stopping 1
Why Tapering Matters
While bupropion is not traditionally associated with the severe withdrawal syndromes seen with SSRIs or SNRIs, the FDA's explicit tapering recommendation exists for important reasons:
Neuropsychiatric considerations: Bupropion affects dopamine and norepinephrine reuptake. Abrupt discontinuation can theoretically precipitate mood changes, though the evidence base is limited compared to other antidepressants 2.
Seizure risk management: Given bupropion's dose-dependent seizure risk, gradual dose reduction provides a safety margin, particularly in patients with risk factors 3.
Clinical Context from Broader Antidepressant Literature
While specific bupropion discontinuation studies are sparse, the broader antidepressant literature informs best practices:
- General antidepressant tapering: Evidence suggests that abrupt discontinuation of antidepressants increases relapse risk (HR 2.09-2.97) compared to continuation 4
- Withdrawal symptoms: At least 50% of patients experience withdrawal symptoms when stopping antidepressants, with risk increasing with longer duration of use 5, 6
- Optimal tapering approach: For higher-risk patients or those with previous difficulty stopping, very gradual tapering over weeks to months may be necessary 6, 4
Practical Implementation
Standard approach (per FDA label):
- Reduce from 300 mg to 150 mg once daily
- Continue 150 mg for at least several days to 1-2 weeks (though duration not specified in label)
- Then discontinue
For higher-risk patients (longer duration of use, previous withdrawal symptoms, psychiatric comorbidities):
- Consider more gradual tapering: 300 mg → 150 mg (2-4 weeks) → 75 mg (if available or via splitting) → discontinue
- Monitor every 2-4 weeks during taper 6
- Be prepared to slow or pause taper if symptoms emerge
Key Caveats
Distinguish withdrawal from relapse: Withdrawal symptoms (irritability, mood changes, insomnia) can mimic depression relapse. True withdrawal typically peaks within 1-2 weeks and resolves, while relapse persists and worsens 5, 4.
Combination products: For bupropion-naltrexone combinations used for weight management or smoking cessation, the same tapering principles apply, with weekly dose reductions recommended 7.
Smoking cessation context: When bupropion is used for smoking cessation (typically 7-12 weeks), guidelines do not mandate tapering for short-term use, though monitoring for neuropsychiatric symptoms remains important 2, 3.
Avoid abrupt discontinuation: The FDA label's explicit tapering instruction, combined with general antidepressant discontinuation evidence, makes clear that abrupt cessation should be avoided when clinically feasible 1.